This concept sees PD and HD not as mutually exclusive therapies,

but complementary to one another, a concept also supported by Blake17 and Alloatti et al.18 Panagoutsos et al.8 found that in their 300 patient cohort, those commencing on PD and then transferring to HD (when RRF deteriorated) had a better survival at 5 years than those who stayed on PD. Patients starting and remaining on HD had a similar 5-year survival to those changing modality. When interpreting this study in the context of the previous studies, there is a survival benefit to commencing renal replacement therapy with PD, particularly if the patient is younger and has limited comorbidities. The survival benefit does disappear between 2–5 years, during which time the patient is either transplanted or discusses a timely change to HD. For the elderly patients with diabetes, or cardiac comorbidities, https://www.selleckchem.com/Wnt.html the survival benefit of commencing with PD therapy is less pronounced and varies according to country. Kidney Disease Outcomes Quality Initiative: No recommendation. UK Renal Association: No recommendation. Canadian Society of Nephrology: No recommendation. European Best Practice Guidelines: These guidelines state that the type of

dialysis method that should be favoured check details as first therapy is unsettled at present. There will be debate regarding this issue until the concept of the ‘integrative care approach’

(starting renal replacement Acetophenone therapy with PD) gains more scientific merit. International Guidelines: No recommendation. More prospective cohort studies are required comparing home dialysis therapies (HD or PD) with hospital-based or satellite HD. A body of evidence is yet to emerge comparing mortality rates of home dialysis therapies – HD and PD, including nocturnal therapies. Melissa Stanley has no relevant financial affiliations that would cause a conflict of interest according to the conflict of interest statement set down by CARI. “
“C3 glomerulonephritis (C3GN) is a recently described disease that is related to membranoproliferative glomerulonephritis (MPGN). We retrospectively compared the frequencies, clinical characteristics, treatment modalities, and outcomes of C3GN and MPGN in a cohort of Japanese children. Children who were pathologically diagnosed with MPGN (type I or III) in our hospital were divided into two groups based on immunofluorescence imaging of renal biopsies: children with MPGN induced by classical complement pathway activation (classical MPGN) and children with C3GN. Of 14 children with MPGN (five boys), four had classical MPGN, eight had C3GN, and two had unclassifiable glomerulonephritis. Four children with classical MPGN and seven with C3GN received methylprednisolone pulse therapy followed by oral prednisolone for 2 years (MPT+PSL therapy).